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Abstract
Background: Brucella abortus is a facultative intracellular pathogen that mainly infects cattle and
humans. Current vaccines rely on live attenuated strains of B. abortus, which can revert to their
pathogenic status and thus are not totally safe for use in humans. Therefore, the development of
mucosal live vaccines using the food-grade lactic acid bacterium, Lactococcus lactis, as an antigen
delivery vector, is an attractive alternative and a safer vaccination strategy against B. abortus. Here,
we report the construction of L. lactis strains genetically modified to produce B. abortus GroEL heat-
shock protein, a candidate antigen, in two cellular locations, intracellular or secreted.
Results: Only the secreted form of GroEL was stably produced in L. lactis, suggesting a detrimental
effect of GroEL protein when intracellularly produced in this bacterium. Only trace amounts of
mature GroEL were detected in the supernatant fraction of induced lactococcal cultures, and the
GroEL precursor remained stacked in the cell fraction. Attempts to raise the secretion yields were
made, but even when GroEL was fused to a synthetic propeptide, secretion of this antigen was not
improved.
Conclusion: We found that L. lactis is able to produce, and to secrete, a stable form of GroEL into
the extracellular medium. Despite the low secretion efficiency of GroEL, which suggest that this
antigen interacts with the cell envelope of L. lactis, secretion seems to be the best way to achieve
both production and protein yields, regardless of cellular location. The L. lactis strain secreting
GroEL has potential for in vivo immunization.
Background
Brucella abortus, a facultative intracellular Gram-negative
bacterium, is the causative agent of brucellosis: a world-
wide zoonosis that causes abortion and infertility in cat-
tle, as well as undulant fever, arthritis, endocarditis,
meningitis and osteomyelitis in humans [1]; therefore it
constitutes both an economic and a public health prob-
lem [2]. Current brucellosis vaccines are composed of live
attenuated B. abortus strains (e.g. S19, RB51). However,
most of them present major drawbacks that limit the con-
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trol of brucellosis: (i) they are pathogenic for humans; (ii)
they cause abortion when administered to pregnant
females; and (iii) they interfere with the diagnosis of
infected animals [2-5]. There is thus a need for the devel-
opment of more effective and safer vaccines to better con-
trol brucellosis.
Current strategies for the development of new vaccines
against B. abortus have been based on the identification of
immunodominant antigens able to elicit a cellular
immune response [6-9], which is required to resist the
intracellular location of this pathogen [10-12]. GroEL, a
well-known heat-shock protein present in various patho-
gens, can elicit humoral and cellular immune responses in
different host models [13-15]. Moreover, cattle and mice
infected with B. abortus exhibit an immune response to
GroEL [8,16,17]. Taken together, these observations sug-
gest the potential of GroEL as a candidate antigen for the
development of a brucellosis vaccine.
Recently, new strategies to develop vaccines against infec-
tious diseases have been reported [18-20]. As most patho-
genic microorganisms initiate infection through mucosal
surfaces, recent approaches have focused on mucosal
immunization [21]. A variety of live, attenuated-bacterial
strains have been used as carriers to deliver foreign anti-
gens to mammalian hosts [22-25]; however, they still
retain invasiveness and virulence properties that limit
their use in humans. Lactic acid bacteria (LAB) are prom-
ising candidates for the development of new, safe,
mucosal vaccines, and different from attenuated patho-
genic bacteria, they are food-grade, non-invasive and non-
pathogenic organisms [26,27]. Mucosal immunization
with genetically modified LAB to produce bacterial and
viral antigens has been shown to elicit an immune
response [28-32]. We have been particularly interested in
the development of a new mucosal vaccine against brucel-
losis using Lactococcus lactis, the model LAB, as a delivery
vector. Moreover, as L. lactis is a non-commensal and tran-
sient bacterium in the digestive tract, induction of immu-
notolerance to an L. lactis-associated antigen is
diminished.
We previously reported targeted production (i.e. in the
cytoplasm, in the cell wall or into the extracellular
medium) of the immunogenic B. abortus ribosomal pro-
tein L7/L12 in L. lactis [33]. Oral administration of a L. lac-
tis strain producing a cytoplasmic form of L7/L12 induced
partial protection against this pathogen in mice [29]. We
have now cloned the B. abortus groEL into three different
nisin-inducible expression vectors [33,34] for production
of GroEL in two cellular locations, intracellular and
secreted. Only the secreted form of GroEL was stably pro-
duced in L. lactis. This new strain has potential for use in
vaccination programs to prevent brucellosis.
Results and discussion
Construction of recombinant L. lactis strains to produce 
either cytoplasmic or secreted forms of GroEL
As the protective response depends on the antigen, the
delivery system and the location of the antigen
[25,35,36], we evaluated the impact of B. abortus GroEL
production by L. lactis in two different cellular locations,
intracellular and secreted. Two expression vectors were
initially constructed, pCYT:groEL and pSEC:groEL for cyto-
plasmic and secreted GroEL production, respectively.
These plasmids are derived from two broad-host-range
expression vectors, pCYT:Nuc and pSEC:Nuc (Table 1;
[34]); pCYT:Nuc harbors a transcriptional fusion between
the ribosome-binding site (RBSusp45) of the usp45  gene
[37] and the DNA sequence encoding the mature part of
the staphylococcal nuclease, NucB [38] (Table 1), and
pSEC:Nuc harbors a transcriptional fusion between
RBSusp45 and the DNA sequence encoding the signal pep-
tide (SPusp45) of Usp45 plus nucB (Table 1). In both cases,
nucB expression is under the control of the nisin-inducible
promoter, PnisA [39].
The vector to target GroEL protein in the cytoplasm of L.
lactis, pCYT:groEL, was obtained as follows: A 1641-bp
Table 1: Bacterial strains and plasmids used in this work
Strain/plasmid Relevant characteristics Source
Bacterial strains
E. coli TG1 supE, hsd, ∆5, thi, ∆ (lac-proAB), F'(traD36 proAB-lacZ∆M15)[ 5 0 ]
L. lactis NZ9000 L. lactis subsp. cremoris (derivative strain of MG1363, carrying nisRK genes on the chromosome) [51]
Plasmids
pMal-GroEL pMal expression vector carrying the B. abortus groEL gene [17]
pCYT:Nuc pWV01/Cmr; expression vector containing the fusion rbsUsp45::nucB, under the control of PnisA [34]
pSEC:Nuc pWV01/Cmr; expression vector containing the fusion rbsUsp45::spUsp45::nucB, under the control of PnisA [34]
pSEC:LEISS:Nuc pWV01/Cmr; expression vector containing the fusion rbsUsp45::spUsp45::LEISS::nucB, under the control of PnisA [33]
pCYT:groEL pWV01/Cmr; plasmid containing the fusion rbsUsp45::groEL, under the control of PnisA This work
pSEC:groEL pWV01/Cmr; plasmid containing the fusion rbsUsp45::spUsp45::groEL, under the control of PnisA This work
pSEC:LEISS:groEL pWV01/Cmr; plasmid containing the fusion rbsUsp45::spUsp45::LEISS::groEL, under the control of PnisA This workMicrobial Cell Factories 2006, 5:14 http://www.microbialcellfactories.com/content/5/1/14
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DNA fragment encoding GroEL was PCR-amplified from
the vector pMal-GroEL (Table 1; [17]). Two oligonucle-
otides, containing two restriction sites, were designed on
the basis of the genomic DNA sequence from the B. abor-
tus groEL gene (Genbank accession number M82975): i)
CTFgroEL  for the coding strand: 5'- GGATGCATGCT-
GCAAAAGACGTA -3', in which the NsiI site is underlined;
and ii) CTRgroEL  for the complementary strand: 5'-
CGGAATTCTTAGAAGTCCATGCC -3', in which the EcoRI
site is underlined. The resulting amplified product was
treated with NsiI and EcoRI and then cloned into purified
backbone isolated from NsiI-EcoRI-cut pCYT:Nuc expres-
sion vector, replacing the DNA sequence encoding for
NucB (Table 1; Figure 1A). To obtain the vector to target
GroEL protein to the extracellular medium (i.e. secreted)
of  L. lactis, pSEC:groEL, the following procedures were
adopted: The groEL gene was PCR amplified from pMal-
GroEL (Table 1; [17]). The oligonucleotides were: i) SCF-
Schematic representation of expression cassettes for controlled and targeted GroEL production in L. lactis Figure 1
Schematic representation of expression cassettes for controlled and targeted GroEL production in L. lactis. For 
details of plasmid constructions, see the text and Table 1. PnisA: nisin-inducible promoter; rbsUsp45: ribosome binding site of 
Usp45 gene; spUsp45: DNA sequence encoding the signal peptide of Usp45 gene; LEISS: DNA sequence encoding the 
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groEL  for the coding strand: 5'- GGATGCATCAGCT-
GCAAAAGACGTA -3', in which the NsiI site is underlined
and CA (in bold) was added to adapt the reading frame of
spUsp45; and ii) SCRgroEL for the complementary strand: 5'-
CGGTTAACTTAGAAGTCCATGCC -3', in which the HpaI
site is underlined. The PCR product was then digested by
NsiI and HpaI and cloned into purified backbone isolated
from NsiI-EcoRV-cut pSEC:Nuc expression vector, again
replacing the DNA sequence encoding for NucB (Table 1;
Figure 1B).
In both cases, pCYT:groEL  and pSEC:groEL  were first
obtained in E. coli TG1 and then transferred into L. lactis
NZ9000 [40,41]. All constructions were confirmed by
DNA sequencing. Surprisingly, during procedures to
recover  L. lactis NZ9000 colonies harboring the
pCYT:groEL plasmid, we observed that such colonies did
not grow normally, taking around four days to be visible
in selective M17-agar plates; while L. lactis NZ9000 colo-
nies harboring the pSEC:groEL plasmid, hereafter called
NZ(pSEC:groEL), normally grew in 18–24 hours. Moreo-
ver, when some colonies were grown in selective liquid
medium, they reached a maximum OD600nm of around
0.05, after overnight culture, compared to OD600nm of
around 1.5 for NZ(pSEC:groEL). One hypothesis to
explain this phenomenon is that the pCYT:groEL plasmid
has a basal expression level, and GroEL could therefore
interact with lactococcal proteins, generating detrimental
disorders in the host cellular metabolism. Prokaryotic
chaperones are functionally well conserved and, once
cloned in a foreign host, a chaperone may interact with
the host proteins [42,43]. We already observed similar
phenomena in L. lactis with various viral, prokaryote and
eukaryote proteins (for a review see [44]); lactococcal
strains engineered to produce cytoplasmic protein forms
had a reduced growth rate, and consequent absent or low
levels of heterologous protein production.
L. lactis is able to produce a stable secreted form of GroEL
As we did not succeeded in obtaining an L. lactis strain
that produced GroEL in the cytoplasm, we continued the
analysis of the L. lactis strain that produced a secreted
form of GroEL. To evaluate whether this recombinant
strain is able to produce and export GroEL outside the cell,
we performed Western blot analysis of proteins extracted
from cell (C) and supernatant (S) fractions of induced and
non-induced NZ(pSEC:groEL) cultures. Analysis of
induced NZ(pSEC:groEL) samples revealed only one band
in the C fraction, with an expected size of around 60 kDa,
which corresponds to the GroEL precursor
(SPUsp45::GroEL) (Figure 2). In the S fraction, we also
detected only one band at the expected size for mature
GroEL (around 57 kDa) (Figure 2). However, in this latter
case, only trace amounts of mature GroEL could be
detected in the S fraction; this indicates that the GroEL
precursor remained stacked in the C fraction, probably
associated with the cell envelope. Thus, secreted form of
GroEL seems not to be interfering with the host physiol-
ogy due to the fact that GroEL is fused to SPUsp45 which in
turn targets the hybrid protein to the extracellular
medium, or at least, in this case, to the cell envelope.
SPUsp45::GroEL might undergo rapid folding right after
their synthesis, which interferes with (or hampers) the
secretion process. Moreover, sometimes, secreted proteins
require subsequent folding and maturation steps to
acquire their active conformation. The secretion efficiency
(SE; the ratio of mature protein secreted in the superna-
tant as a fraction of intracellular content) was estimated to
be ~3–5%. Inefficiency in B. abortus GroEL secretion was
previously reported by Leclerq et al. (2002; [17]), using
the mammalian expression vector pCMV-tPA, containing
a signal peptide sequence fused to groEL. Very low levels
of GroEL were observed both in the C and S fractions from
D17 cells (dog osteosarcoma cell line), in spite of the pres-
ence of GroEL transcripts. In this case, a possible explana-
tion is that as B. abortus GroEL is able to associate with the
bacterial surface through the type IV secretion system and
to interact directly or indirectly with cellular prion protein
(PrPC) on host cells [45], these properties may interfere
with the secretion process. On the other hand, in the case
of L. lactis, low GroEL SE may be due to an interaction
with the cell envelope, mediated by a secretion system
other than the type IV system, which is not present in lac-
tococcal cells [46]. A similar effect was already observed in
a L. lactis strain designed to produce a secreted form of
bovine rotavirus nonstructural protein 4 (NSP4) [47]. No
NSP4 was detected in the S fraction, and both precursor
and mature protein were only detected in the C fraction.
The authors suggest that NSP4 could be associated with
the cell envelope, probably due to hydrophobic domains
that prevent its release into the medium.
Interestingly, the secreted GroEL seems not to be a target
for the unique L. lactis housekeeping extracellular pro-
tease (HtrA; [48]), since degradation products were not
detected by Western blotting (see Methods section) in the
S fraction of induced NZ(pSEC:groEL) cultures samples
(Figure 2). As previously reported [48,49], a number of
exported heterologous proteins already produced in wild
type L. lactis strains are recognized by this protease as for-
eign, being degraded during translocation steps across the
cell envelope. We suppose that this did not occur in our
strain because B. abortus GroEL seems to be structurally
and functionally well-conserved. Comparison analyses of
GroEL amino acid sequence from B. abortus S19 (acces-
sion number: AAA22997) and L. lactis IL1403 (accession
number: NP266550) showed that these sequences possess
around 54% identity, and both sequences harbor a
highly-conserved Cpn60 chaperonin motif.Microbial Cell Factories 2006, 5:14 http://www.microbialcellfactories.com/content/5/1/14
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In conclusion, even though low SE was observed, L. lactis
was able to produce and target B. abortus GroEL to the
extracellular medium. Moreover, degradation products
related to lactococcal HtrA activity were not observed in
the S fraction from induced NZ(pSEC:groEL) culture sam-
ples, and so L. lactis seems to be able to produce a stable
form of GroEL.
Synthetic propeptide does not enhance secretion 
efficiency of GroEL
Previous studies showed that the synthetic propeptide
LEISSTCDA (hereafter called LEISS) can enhance SE of
heterologous proteins in L. lactis (for a review see [44]).
We examined whether LEISS could improve SE of GroEL.
For this purpose, we used pSEC:LEISS vector, which is a
derivative of pSEC:Nuc vector, plus a DNA fragment
encoding for LEISS synthetic propeptide fused between
SPUsp45  and  nucB  (Table 1; [33]). The DNA fragment
encoding GroEL was cloned into pSEC:LEISS, using the
same experimental procedure as that used for cloning the
secreted form of GroEL (see above). The resulting plas-
mid, pSEC:LEISS:groEL (Table 1; Figure 1C), was estab-
lished in L. lactis NZ9000 [NZ(pSEC:LEISS:groEL)] and
GroEL production and secretion was then examined by
Western blot analysis. LEISS did not exert any significant
influence on SE of GroEL, since comparable amounts of
GroEL were present in the S fraction from both
NZ(pSEC:groEL) and NZ(pSEC:LEISS:groEL) (Figure 2).
Note that GroEL is the second reported protein in which
LEISS has no influence on the SE. The first one was the
hybrid protein Nuc-NSP4 [49].
Conclusion
This work is part of an ongoing project geared to produc-
ing and testing new B. abortus antigens that could be used
as alternative vaccines against brucellosis. Here we have
described the construction of lactococcal strains that pro-
duce B. abortus GroEL heat-shock protein, a well-known
Western blot analyses of nisin-induced L. lactis NZ9000 (pSEC:groEL) and (pSEC:LEISS:groEL) strains Figure 2
Western blot analyses of nisin-induced L. lactis NZ9000 (pSEC:groEL) and (pSEC:LEISS:groEL) strains. Protein 
extracts of culture samples of NZ(pSEC:groEL) and NZ(pSEC:LEISS:groEL) strains were prepared from cell (lanes C) and super-
natant (lanes S) fractions and were analyzed by Western blotting using anti-GroEL antibodies. The migration positions of pre-
cursor- and mature-GroEL forms are indicated by arrows. Purified GroEL (around 12 µg) was used as the standard (lane Std), 
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immunodominant target for both humoral and cellular
immune responses [8,16]. L. lactis was able to produce,
and to secrete, a stable form of GroEL into the extracellu-
lar medium. Despite concerns about the low SE of GroEL,
which suggest that this antigen interacts with the cell
envelope of L. lactis, secretion seems to be the best way to
achieve both production and protein yields, regardless of
cellular location. Therefore, this new L. lactis strain has
potential for oral immunization trials. Immunization
assays using this strain are now in progress and will allow
definition of the immune response and the level of pro-
tection that GroEL confers against challenge with B. abor-
tus.
Methods
Bacterial strains, growth conditions and plasmids
Escherichia coli TG1 (Table 1; [50]) was aerobically grown
in Luria-Bertani medium at 37°C. L. lactis NZ9000 (Table
1; [51]) was grown in M17 medium supplemented with
0.5% glucose (GM17) at 30°C. When required, antibiot-
ics were added as follows: ampicillin (100 µg/ml) and
chloramphenicol (10 µg/ml) for E. coli, and chloram-
phenicol (10 µg/ml) for L. lactis.
Lactococcal plasmids pCYT:Nuc, pSEC:Nuc and
pSEC:LEISS:Nuc (Table 1; [33,34]) were used in order to:
i) control the expression of the B. abortus groEL, through a
nisin-inducible promoter, PnisA [39]; and ii) target the B.
abortus GroEL either to the cytoplasm or to the extracellu-
lar medium. For further details about plasmid construc-
tions, see the results and discussion section.
DNA manipulations
General DNA manipulation techniques were carried out
according to standard procedures [40]. Unless otherwise
indicated, DNA restriction and modification enzymes
were used as recommended by the suppliers. DNA frag-
ments were isolated from agarose gels with the Concert™
Rapid Gel Extraction System (Gibco BRL). PCR amplifica-
tions were made using Taq DNA polymerase (Invitro-
gen™) in a DNA thermocycler (MJ Research, Inc.). Plasmid
DNA from E. coli and L. lactis was isolated, as previously
described [40,41]. DNA sequencing was carried out on
double-stranded plasmid DNA by the dideoxy chain ter-
mination method [52] with MegaBACE Sequencing Sys-
tems (Amersham Biosciences). Routine amino acid
homology searches were performed by the "Basic Local
Alignment Search Tool" (BLAST; [53]), service of the
National Center for Biotechnology Information (NCBI).
Amino acid sequence similarity searches were performed
by the ClustalW [54], service of the European Bioinfor-
matics Institute. Further analyses for the identification of
protein-conserved motifs were performed with the "Pro-
tein Families Database" (Pfam; [55]), service of the Well-
come Trust Sanger Institute.
Conditions of nisin induction
For induction of the nisin promoter, overnight cultures of
recombinant  L. lactis strains harboring pCYT:groEL,
pSEC:groEL or pSEC:LEISS:groEL (Table 1) were used to
inoculate fresh medium at a dilution of 1/100. At an opti-
cal density at 600 nm (OD600) of ~0.4, 1 ng/ml of nisin
(Sigma) was added and cultures were incubated for one
hour, before performing cell fractionation and protein
extractions.
Protein extractions and Western blotting
Protein samples were prepared from L. lactis cultures, as
previously described [56], except for the introduction of
protease inhibitors and mild precipitation procedures.
Briefly, protein samples were prepared from 2 ml of cul-
tures, and the cell pellet and supernatant were treated sep-
arately. To inhibit proteolysis in supernatant samples, 1
mM phenylmethylsulfonyl fluoride (PMSF) and 10 mM
dithiothreitol (DTT) were added. Proteins were then pre-
cipitated by addition of 100 µl of 100% trichloroacetic
acid, incubated for 10 min on ice, and then centrifuged 10
min at 17,500 × g at 4°C. For the cell fraction, TES-Lys
buffer (25% sucrose, 1 mM EDTA, 50 mM Tris-HCl [pH
8.0], lysozyme [10 mg/ml]) was complemented with 1
mM PMSF and 10 mM DTT. Twelve percent sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blot, using anti-GroEL antibodies
[17], were performed, as described previously [40].
Immunodetections were carried out with protein G horse-
radish peroxidase conjugate (BioRad) and the ECL Kit
(Dupont-NEN), as recommended by the suppliers. Quan-
tification of GroEL was performed by scanning blots after
immunodetection, comparing the signals to those of
known amounts of purified GroEL [38].
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